Long-term blinded placebo-controlled study of SNT-MC17/idebenone in the dystrophin deficient mdx mouse: cardiac protection and improved exercise performance - sprookjes - yvandenbroek - TriplyDB

Long-term blinded placebo-controlled study of SNT-MC17/idebenone in the dystrophin deficient mdx mouse: cardiac protection and improved exercise performance

Long-term blinded placebo-controlled study of SNT-MC17/idebenone in the dystrophin deficient mdx mouse: cardiac protection and improved exercise performance

http://www.wikidata.org/entity/Q24655319

about

Idebenone for the treatment of Duchenne muscular dystrophy Idebenone for the treatment of Duchenne muscular dystrophy Current and emerging treatment strategies for Duchenne muscular dystrophy Oxidative Stress-Mediated Skeletal Muscle Degeneration: Molecules, Mechanisms, and Therapies Metabogenic and Nutriceutical Approaches to Address Energy Dysregulation and Skeletal Muscle Wasting in Duchenne Muscular Dystrophy Assessment and management of respiratory function in patients with Duchenne muscular dystrophy: current and emerging options An experimental approach to study the function of mitochondria in cardiomyopathy Pre-clinical drug tests in the mdx mouse as a model of dystrophinopathies: an overview Proteomic profiling of the dystrophin-deficient mdx phenocopy of dystrophinopathy-associated cardiomyopathy Anti-inflammatory drugs for Duchenne muscular dystrophy: focus on skeletal muscle-releasing factors Prevention of exercised induced cardiomyopathy following Pip-PMO treatment in dystrophic mdx mice.Long-term improvement in mdx cardiomyopathy after therapy with peptide-conjugated morpholino oligomers.Arginine metabolism by macrophages promotes cardiac and muscle fibrosis in mdx muscular dystrophy.Proteomic Profiling of the Dystrophin-Deficient MDX Heart Reveals Drastically Altered Levels of Key Metabolic and Contractile Proteins.Membrane sealant Poloxamer P188 protects against isoproterenol induced cardiomyopathy in dystrophin deficient mice.Late-life rapamycin treatment reverses age-related heart dysfunction.Pharmacologic management of Duchenne muscular dystrophy: target identification and preclinical trials Molecular diagnosis of duchenne muscular dystrophy: past, present and future in relation to implementing therapies Sildenafil reverses cardiac dysfunction in the mdx mouse model of Duchenne muscular dystrophy.Endpoint measures in the mdx mouse relevant for muscular dystrophy pre-clinical studies.Histologic muscular history in steroid-treated and untreated patients with Duchenne dystrophy Emerging drugs for Duchenne muscular dystrophy Mitochondria as a drug target in ischemic heart disease and cardiomyopathy Novel compounds for the treatment of Duchenne muscular dystrophy: emerging therapeutic agents Alterations in mitochondrial function as a harbinger of cardiomyopathy: lessons from the dystrophic heart.Cardiomyopathy of Duchenne muscular dystrophy: current understanding and future directions.Ongoing therapeutic trials and outcome measures for Duchenne muscular dystrophy.Treatment of dystrophin cardiomyopathies.Oxidative stress in muscular dystrophy: from generic evidence to specific sources and targets.Drug Discovery of Therapies for Duchenne Muscular Dystrophy.Effectiveness of Coenzyme Q10 on echocardiographic parameters of patients with Duchenne muscular dystrophy.Pharmacological therapeutics targeting the secondary defects and downstream pathology of Duchenne muscular dystrophy Effects of glucocorticoids and idebenone on respiratory function in patients with duchenne muscular dystrophy.Treating muscular dystrophy by stimulating intrinsic repair.Tempol Supplementation Restores Diaphragm Force and Metabolic Enzyme Activities in mdx Mice.Inflammatory predisposition predicts disease phenotypes in muscular dystrophy.At the Crossroads of Clinical and Preclinical Research for Muscular Dystrophy-Are We Closer to Effective Treatment for Patients?

P2860

Q24201942-B1784EFD-0332-4280-9B90-667D4244991C Q24236662-52BA05A7-A51D-4EE5-8587-C6787B823820 Q26741535-43DFF7FB-20E6-462A-AAD8-427E1206D5F0 Q26769962-5AEE2D2E-2F07-4BB0-81BC-C0D8E9B428B1 Q26772002-83BAF9CB-322B-4339-A585-E99B093A53B6 Q26785627-460E462A-57E3-4586-BDEC-0E0E2A08A0C5 Q26801342-621A2811-C9F1-409D-BF14-05CA81FF0240 Q26849430-2322B7DA-83FF-46F0-9AD5-E1A3E90D2C38 Q27006945-1E0A05FE-389D-4B7C-A465-7DAC24D0DC56 Q28069464-6BBBA9E6-02E7-4794-9EF8-627794723954 Q30626615-6D3168AF-EDB2-4D04-AC67-ECAECF788A51 Q33573648-480D8768-222A-4CBC-A0CA-A6867F320BAD Q33588636-F612DB77-4124-48CC-A3CC-561C77C12F3C Q33871052-4EE3F577-0073-4B7E-97D6-993C48267B2E Q33901556-E95EF6CC-F452-4E6C-AC71-C08F99DDAD3C Q33903651-D6149FE8-203C-4126-9112-2E93BAFFD2AE Q34152280-14E64534-2262-433D-8E54-7ABB9F897C08 Q34215825-E59E29FC-9ED4-4316-B7A7-3D2B9193F697 Q34279254-D37217F0-7ADE-449D-BAE1-3C88824B8B81 Q35690856-12600C15-CC64-4793-A3A4-155F4468935B Q36327073-44211AB0-1D6A-4334-A20F-85A752FC3251 Q36363716-88DC7F99-DAAD-41AA-9DD6-03CF87A8F9B3 Q36426316-9E2D4B97-B008-4489-A684-EAC4E6CA71AD Q36925191-0284ABF0-0586-4C78-8B27-FABDD3E471A4 Q37601041-E47E73F3-BCCF-44F6-8DC8-81513B6BBED5 Q37889770-10BBE76E-5F74-420A-B602-46411D873EDC Q38115148-5518EE67-A2DD-4F7C-BBA8-BDD50FB221FF Q38178061-ED1582A7-3AC8-403A-80F5-CD2ADA998BFD Q38195206-EF088B56-63E2-405B-9BC2-BCDAC0BF80DD Q38480698-7F8B44FE-361B-4C41-960E-CA86C729A797 Q38810069-F8FA5122-A3AF-42C8-BD8C-A1C6D187809A Q39410461-E6746D52-7D15-442A-A82F-286159306A94 Q39524805-387E98D2-0703-45DC-B553-C467E0024E1B Q46403550-D45B45E2-6FD4-4C27-892E-8C8C40A5E52C Q47100974-C9E161FA-29D1-4069-BB7E-83A0B1435F52 Q47153445-0676F1E8-7881-4E02-A4C7-13BAF8BA95E1 Q55361250-0D35973F-7516-4484-95E6-36B1EDECF808

P2860

Long-term blinded placebo-controlled study of SNT-MC17/idebenone in the dystrophin deficient mdx mouse: cardiac protection and improved exercise performance

http://www.wikidata.org/entity/Q24655319

description

2009 nî lūn-bûn

@nan

2009 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

Long-term blinded placebo-cont ...... improved exercise performance

@ast

Long-term blinded placebo-cont ...... improved exercise performance

@en

Long-term blinded placebo-cont ...... improved exercise performance

@nl

type

label

Long-term blinded placebo-cont ...... improved exercise performance

@ast

Long-term blinded placebo-cont ...... improved exercise performance

@en

Long-term blinded placebo-cont ...... improved exercise performance

@nl

prefLabel

Long-term blinded placebo-cont ...... improved exercise performance

@ast

Long-term blinded placebo-cont ...... improved exercise performance

@en

Long-term blinded placebo-cont ...... improved exercise performance

@nl

P1433

Q24655319-F5A325F0-6098-4551-B009-8D7A2FB01C43

P1476

Q24655319-0154C22F-799C-48A8-908C-445427366A89

P2093

Q24655319-133583DE-3911-4791-80DA-C0C626EC8B46

Q24655319-58D65400-DBF0-41B4-957F-8448B2BDEC97

Q24655319-5C8666CD-A85E-4303-819E-141021AC5380

Q24655319-6535B91B-63B7-4E79-BB04-1C7DE55F6C30

Q24655319-80BF705C-F15B-42A2-BBD4-33D1BD80293F

Q24655319-9F42E8B3-2EA7-4891-B5A1-FC93CD7C1608

Q24655319-E0EDCC87-7EE2-404D-B540-C44DFC7DF73B

Q24655319-EE144B28-00DB-4634-994F-126C94B2DC37

Q24655319-FB6C22A4-ED6F-47D1-976B-B63D758CC596

P2860

Q24655319-1A7AB906-3DB3-45C9-9899-BE26F87B94D4

Q24655319-1C3DC355-FB7A-47C6-9B37-229FBFF08D23

Q24655319-22C5BCCE-6D4F-437E-A4D0-A4152E42F204

Q24655319-35BBF04E-C01E-477C-B3B8-EA1AB2CE8346

Q24655319-3F9E85B5-E6BF-4275-A3BF-0C3A2C95729F

Q24655319-5F2E06AE-06AF-4020-BF69-CF6CC62D6F0E

Q24655319-7F574A76-AEA6-4888-9A35-651172E05BD7

Q24655319-93F959F9-A0CB-453F-91EE-FEF70A7FF7D4

Q24655319-9BC088B0-D5A0-4F72-9406-90A88DD72E07

Q24655319-C3F61A43-332F-4304-9B04-0D95CB840B31

P304

Q24655319-C073D93F-4F9A-496E-B4F1-CBC5C67FAFA1

P31

Q24655319-1F44EE27-64A8-438B-825D-0AE431040627

P3181

Q24655319-5C2129F9-2B84-4D97-B722-C08C84D4C215

P356

Q24655319-1A2EA6E6-E48C-430C-B11B-2CA7514BBAB7

P407

Q24655319-AC796737-91BE-40C9-B305-18B072F467CB

P433

Q24655319-A100F0CA-FF22-4F6C-93AC-46240F30DB3A

P478

Q24655319-E48C7118-F862-4D2B-8C4B-F7095A8274CD

P50

Q24655319-308536E1-881D-4B79-A943-F86C4F5EB7AA

Q24655319-A02CE94C-11B6-46B7-9A7D-D58540BE397D

Q24655319-E3D56320-27CF-41D5-923D-F21F7CBE059D

P577

Q24655319-ACDE0682-287F-420D-AB79-A55CBEC724B8

P5875

Q24655319-42B64520-EE7E-4D96-9AC0-FBC0993C21EB

P698

Q24655319-E6E86BCE-3667-40AA-975C-ACBF9ABB303E

P921

Q24655319-2A02EE3E-DC60-49F2-A9FC-F1B3EDF18D0E

P932

Q24655319-C637B902-6536-4EF0-A42C-C1F85F0AFD7B

P3181

P356

P1433

European Heart Journal

P1476

Long-term blinded placebo-cont ...... improved exercise performance

@en

P2093

Alejandro Jara

http://www.w3.org/2001/XMLSchema#string

An Van Den Bergh

http://www.w3.org/2001/XMLSchema#string

Gerry Van der Mieren

http://www.w3.org/2001/XMLSchema#string

Gunnar M Buyse

http://www.w3.org/2001/XMLSchema#string

Isabelle Courdier-Fruh

http://www.w3.org/2001/XMLSchema#string

Jan D'hooge

http://www.w3.org/2001/XMLSchema#string

Luc Mertens

http://www.w3.org/2001/XMLSchema#string

Michael Erb

http://www.w3.org/2001/XMLSchema#string

Thomas Meier

http://www.w3.org/2001/XMLSchema#string

P2860

X chromosome-linked muscular dystrophy (mdx) in the mouse

Early onset of lipofuscin accumulation in dystrophin-deficient skeletal muscles of DMD patients and mdx mice.

Macrophages promote muscle membrane repair and muscle fibre growth and regeneration during modified muscle loading in mice in vivo.

The heart in human dystrophinopathies.

Cardiomyopathy in muscular dystrophies.

Chemistry, toxicology, pharmacology and pharmacokinetics of idebenone: a review.

Idebenone. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in age-related cognitive disorders.

Patients with dystrophinopathy show evidence of increased oxidative stress.

Evidence of early impairments in both right and left ventricular inotropic reserves in children with Duchenne's muscular dystrophy.

Idebenone delays the onset of cardiac functional alteration without correction of Fe-S enzymes deficit in a mouse model for Friedreich ataxia.

P304

116-24

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

3817492

http://www.w3.org/2001/XMLSchema#string

P356

10.1093/EURHEARTJ/EHN406

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

30

http://www.w3.org/2001/XMLSchema#string

P50

Patrizia Barzaghi

P577

2009-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

23249723

http://www.w3.org/2001/XMLSchema#string

P698

18784063

http://www.w3.org/2001/XMLSchema#string

P921

P932

2639086

http://www.w3.org/2001/XMLSchema#string